Internal Medicine, Hematology & Oncology · Scottsdale, AZ
NPI
1174752828
Since 2009
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
13400 E Shea Blvd
Scottsdale, AZ, 85259
Phone (480) 301-8000
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.0M
93,357 services
Medicare patients, 2024
746
Average age 74
Drug cost, 2024
$4.1M
636 prescriptions
Company payments, 2025
$20K
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Cecilia Y Arana Yi was code J9271 (injection, pembrolizumab, 1 mg), 9,400 times for 34 patients. In total Cecilia Y Arana Yi billed 93,357 services in 159 codes, and Medicare paid $2.0M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-09-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 9,400 | 34 | $42.78 | $402K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 6,750 | 40 | $0.11 | $731 |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 6,480 | 32 | $39.07 | $253K |
| J9267 Injection, paclitaxel, 1 mg | Office | 4,824 | 20 | $0.08 | $392 |
| J9025 Injection, azacitidine, 1 mg | Office | 4,460 | 17 | $0.30 | $1,358 |
| J0897 Injection, denosumab, 1 mg | Office | 1,620 | 17 | $20.56 | $33K |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 1,530 | 25 | $35.96 | $55K |
| J9305 Injection, pemetrexed, not otherwise specified, 10 mg | Office | 1,155 | 11 | $3.11 | $3,595 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 996 | 83 | $0.09 | $89.28 |
| Q5115 Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | Office | 870 | 12 | $25.69 | $22K |
| Q5118 Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | Office | 830 | 12 | $16.50 | $14K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 710 | 57 | $0.76 | $538 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 536 | 54 | $0.07 | $39.7 |
| J9041 Injection, bortezomib, 0.1 mg | Office | 475 | 13 | $1.39 | $662 |
| 99214 Office E&M - Established | Office | 358 | 164 | $88.99 | $32K |
By year: 2022 $3.6M for 166,796 services; 2023 $3.0M for 147,392 services; 2024 $2.0M for 93,357 services.
Medicare prescription drug claims, 2024
In 2024, the drug Cecilia Y Arana Yi prescribed most often to Medicare patients was Acyclovir, with 84 prescriptions and refills. In total Cecilia Y Arana Yi wrote 636 Medicare prescriptions that cost $4.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 84 | 128 | 25 | $1,004 |
| Imatinib Mesylate Generic | 48 | 48 | Under 11 | $37K |
| Hydroxyurea Generic | 48 | 87 | 17 | $866 |
| Ayvakit Avapritinib | 40 | 40 | Under 11 | $1.6M |
| Jakafi Ruxolitinib Phosphate | 36 | 36 | Under 11 | $611K |
| Venclexta Venetoclax | 32 | 32 | Under 11 | $120K |
| Allopurinol Generic | 22 | 42 | Under 11 | $276 |
| Fluconazole Generic | 21 | 31 | Under 11 | $973 |
| Levofloxacin Generic | 20 | 28 | Under 11 | $359 |
| Besremi Ropeginterferon Alfa-2b-Njft | 18 | 18 | Under 11 | $285K |
| Cyclosporine Modified Cyclosporine, Modified | 16 | 20 | Under 11 | $5,011 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 16 | 26 | Under 11 | $91.76 |
| Prochlorperazine Maleate Generic | 14 | 14 | Under 11 | $168 |
| Pegasys Peginterferon Alfa-2a | 14 | 14 | Under 11 | $58K |
| Vonjo Pacritinib Citrate | 12 | 12 | Under 11 | $143K |
Brand drugs: 220 claims; generic drugs: 416 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Cecilia Y Arana Yi $20K ($20K in general payments such as food, travel and fees) from 6 companies. The largest payer was E.R. Squibb & Sons, L.L.C. with $8,543.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.